CanSinoBIO files application in China for COVID-19 vaccine approval

CanSinoBIO said the interim analysis of data from its multi-country trial showed that its candidate, known as Ad5-nCoV, has an efficacy rate of 65.28% at preventing all symptomatic cases and 90.07% at …
( read original story …)